Clinical trial
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary…
NCT00062803 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00062803 |
|---|---|
| Title | SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism |
| Official title | The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary… |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jun 17, 2003 |
| Last update posted | Apr 29, 2009 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Italy and 8 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: